Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myokardia Inc (MYOK)

Myokardia Inc (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,109,291
  • Shares Outstanding, K 53,003
  • Annual Sales, $ 0 K
  • Annual Income, $ -276,210 K
  • 60-Month Beta 2.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.88
Trade MYOK with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.48
  • Number of Estimates 4
  • High Estimate -1.32
  • Low Estimate -1.69
  • Prior Year -1.34
  • Growth Rate Est. (year over year) -10.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.90 +31.21%
on 08/31/20
139.22 -2.08%
on 09/30/20
+32.50 (+31.30%)
since 08/28/20
3-Month
88.60 +53.87%
on 07/14/20
139.22 -2.08%
on 09/30/20
+39.71 (+41.10%)
since 06/30/20
52-Week
42.65 +219.65%
on 04/02/20
139.22 -2.08%
on 09/30/20
+84.18 (+161.42%)
since 09/30/19

Most Recent Stories

More News
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company's Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy...

MYOK : 136.33 (+1.64%)
MyoKardia to Participate in September Investor Conferences

MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences:

MYOK : 136.33 (+1.64%)
MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet

MYOK : 136.33 (+1.64%)
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM

MYOK : 136.33 (+1.64%)
Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society...

MYOK : 136.33 (+1.64%)
MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET....

MYOK : 136.33 (+1.64%)
CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey B. Geske, M.D. has changed. The corrected release follows:...

MYOK : 136.33 (+1.64%)
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM)...

MYOK : 136.33 (+1.64%)
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC's HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction

MYOK : 136.33 (+1.64%)
MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology's Virtual Heart Failure Association Discoveries

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --

MYOK : 136.33 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility...

See More

Key Turning Points

2nd Resistance Point 142.03
1st Resistance Point 139.18
Last Price 136.33
1st Support Level 133.52
2nd Support Level 130.71

See More

52-Week High 139.22
Last Price 136.33
Fibonacci 61.8% 102.33
Fibonacci 50% 90.93
Fibonacci 38.2% 79.54
52-Week Low 42.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar